New York, July 18, 2016 -- Moody's Investors Service, ("Moody's") assigned a Baa2 rating to the proposed senior unsecured notes offering of certain finance subsidiaries of Teva Pharmaceutical Industries Ltd ("Teva"), including Teva Pharmaceutical Finance Netherlands II BV (EUR notes), III BV (US notes) and IV BV (CHF notes). Teva will provide an unconditional guarantee to the proposed notes.
Vollständigen Artikel bei Moodys lesen